Salbutamol vs placebo: Chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in chronic lung disease at 28 days compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings table ‐ Salbutamol vs placebo Chronic lung disease at 28 days · preterm infants (< 37 weeks GA) at risk of chronic lung disease Summary of findings table ‐ Salbutamol showed no clear difference in chronic lung disease at 28 days compared with placebo (low certainty). Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane Headline outcomes only | RR 1.03 [0.78, 1.37] | 1 study · 173 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.